The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway

The diabetes medication canagliflozin (Cana) is a sodium glucose cotransporter 2 (SGLT2) inhibitor acting by increasing urinary glucose excretion and thus reducing hyperglycaemia. Cana treatment also reduces body weight. However, it remains unclear whether Cana could directly work on adipose tissue....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Adipocyte
Main Authors: Yang, Xuping, Liu, Qinhui, Li, Yanping, Tang, Qin, Wu, Tong, Chen, Lei, Pu, Shiyun, Zhao, Yingnan, Zhang, Guorong, Huang, Cuiyuan, Zhang, Jinhang, Zhang, Zijing, Huang, Ya, Zou, Min, Shi, Xiongjie, Jiang, Wei, Wang, Rui, He, Jinhan
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7469612/
https://ncbi.nlm.nih.gov/pubmed/32835596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21623945.2020.1807850
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados